Gynecologic CancersOvarian CancerArt Therapy
Despite having no history of cancer in my family, I received this diagnosis and prognosis. I was thrown completely off balance!
Gynecologic CancersOvarian CancerSexuality & Cancer
Cancer diagnosis, treatment, and recovery can lead to changes in your sexual anatomy, functioning, and your feelings about your sexuality.
Gynecologic CancersOvarian Cancer
In 1997 I was 27, happy, free, and traveling the world as a flight attendant. Newly married and ready to have a baby, I felt strong and invincible. My future was unfolding just as I expected it to. Until the symptoms appeared ever so subtly.
FDA Approvals, News & UpdatesGynecologic CancersNewsworthyOvarian Cancer
In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
Cancer ScreeningCervical CancerGynecologic CancersOvarian Cancer
Dr. Julian Schink, GYN Oncology Chief of Cancer Treatment Centers of America, provides screening tips and recommendations for these 2 most common gynecologic cancers.
Ovarian CancerBiomarkersCancer ScreeningIssue Introductions
In her Introduction to the special edition of CONQUER titled Understanding Biomarkers & Molecular Testing, Lillie D. Shockney, RN, BS, MAS, ONN-CG, briefly explains what biomarkers are, why they are important, and what you should know about them.
As a retired college professor, Dr. McElhiney uses her personal experience with ovarian cancer to advocate for other patients, urging faster development of new treatment options.
Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer.
FDA Approvals, News & UpdatesOvarian Cancer
In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations.
Lynparza Extends Survival by More Than 1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation, Should Become Standard Maintenance Therapy
By Wayne Kuznar
The follow-up results of more than 5 years of the multicenter phase 3 SOLO2 clinical trial of women with ovarian cancer were presented at the 2020 ASCO annual meeting, showing improved survival with the use of Lynparza (olaparib) compared with placebo.
Results 1 - 18 of 18